<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101775</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00620</org_study_id>
    <secondary_id>NCI-2014-00620</secondary_id>
    <secondary_id>NCI 9568</secondary_id>
    <secondary_id>PHL-093</secondary_id>
    <secondary_id>9568</secondary_id>
    <secondary_id>9568</secondary_id>
    <secondary_id>N01CM00032</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>UM1CA186644</secondary_id>
    <secondary_id>UM1CA186705</secondary_id>
    <nct_id>NCT02101775</nct_id>
    <nct_alias>NCT02151292</nct_alias>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II clinical trial studies how well gemcitabine hydrochloride and WEE1
      inhibitor MK-1775 work compared to gemcitabine hydrochloride alone in treating patients with
      ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of
      time. Gemcitabine hydrochloride may prevent tumor cells from multiplying by damaging their
      deoxyribonucleic acid (DNA, molecules that contain instructions for the proper development
      and functioning of cells), which in turn stops the tumor from growing. The protein WEE1 may
      help to repair the damaged tumor cells, so the tumor continues to grow. WEE1 inhibitor
      MK-1775 may block the WEE1 protein activity and may increase the effectiveness of
      gemcitabine hydrochloride by preventing the WEE1 protein from repairing damaged tumor cells
      without causing harm to normal cells. It is not yet known whether gemcitabine hydrochloride
      with or without WEE1 inhibitor MK-1775 may be an effective treatment for recurrent ovarian,
      primary peritoneal, or fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the progression free survival (PFS) of subjects with recurrent
      platinum-resistant ovarian, fallopian tube or primary peritoneal cancer receiving
      gemcitabine (gemcitabine hydrochloride) in combination with AZD 1775 (MK-1775 [WEE1
      inhibitor MK-1775]) compared to subjects receiving gemcitabine in combination with placebo.

      SECONDARY OBJECTIVES:

      I. To evaluate the objective response by Response Evaluation Criteria in Solid Tumors
      (RECIST) 1.1 of patients receiving gemcitabine combined with AZD 1775 (MK-1775) compared to
      patients receiving gemcitabine in combination with placebo.

      II. To evaluate the Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)125 response
      rate of patients receiving gemcitabine combined with AZD 1775 (MK-1775) compared to patients
      receiving gemcitabine in combination with placebo.

      III. To evaluate the overall survival of patients (max 1-year [yr] follow-up) receiving
      gemcitabine combined with AZD 1775 (MK-1775) compared to patients receiving gemcitabine in
      combination with placebo.

      IV. To evaluate the safety and tolerability of the combination of gemcitabine combined with
      AZD 1775 (MK-1775) in patients with recurrent, platinum-resistant ovarian, fallopian tube or
      primary peritoneal cancer.

      V. To evaluate tumor protein p53 (TP53) mutations (presence of mutation and type of
      mutation) as potential predictive factors of benefit (defined as response or
      progression-free survival [PFS] prolongation) to AZD 1775 (MK-1775) and gemcitabine
      treatment.

      VI. To evaluate p53 protein expression by immunohistochemistry as potential predictive
      factors of benefit (defined as response or PFS prolongation) to AZD 1775 (MK-1775) and
      gemcitabine treatment.

      TERTIARY OBJECTIVES:

      I. To evaluate patient reported outcomes using Patient-Reported Outcomes (PRO)-Common
      Terminology Criteria for Adverse Events (CTCAE).

      II. To evaluate the concordance of TP53 mutations in the tumor specimen and TP53 mutations
      determined by tagged-amplicon deep sequencing (Tam-Seq) in circulating tumor DNA.

      III. To correlate the levels circulating DNA TP53 mutations by Tam-Seq with response.

      IV. Validation of phosphorylated-cyclin-dependent cycle 2 (pCDC2) and gamma-H2A histone
      family, member X (H2AX) in skin and tumor tissue as a pharmacodynamic marker of therapy.

      V. To correlate changes in pCDC2 and gamma-H2AX with survival outcomes and response rate.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive WEE1 inhibitor MK-1775 orally (PO) on days 1, 2, 8, 9, 15, and 16
      and gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine
      hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6-8 weeks for up to 1
      year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS evaluated using RECIST version 1.1</measure>
    <time_frame>Time from start of treatment to time to progression or death, whichever occurs first, assessed up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GCIG CA125 response rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or 4 serious adverse events, graded according to the National Cancer Institute CTCAE version 4.0</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response by RECIST version 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Survival estimates will be computed using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p53 protein expression in archival tumor tissue by immunohistochemistry (IHC)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TP53 mutations (presence and type of mutation) by Sanger sequencing</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in levels of circulating DNA TP53 mutations by Tam-Seq</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <description>Levels of circulating DNA TP53 mutations will be correlated with response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gH2AX in skin and tumor tissue</measure>
    <time_frame>Baseline and at day 2 or 9 (course 1)</time_frame>
    <description>Validation of gH2AX as a pharmacodynamic marker of therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in pCDC2</measure>
    <time_frame>Baseline and at day 2 or 9 (course 1)</time_frame>
    <description>Changes in pCDC2 will be correlated with survival outcomes and response rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in pCDC2 in skin and tumor tissue</measure>
    <time_frame>Baseline and at day 2 or 9 (course 1)</time_frame>
    <description>Validation of pCDC2 as a pharmacodynamic marker of therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in pH2AX</measure>
    <time_frame>Baseline and at day 2 or 9 (course 1)</time_frame>
    <description>Changes in pH2AX will be correlated with survival outcomes and response rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcomes using PRO-CTCAE</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>TP53 mutations in circulating tumor DNA by Tam-Seq</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Brenner Tumor</condition>
  <condition>Ovarian Carcinosarcoma</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Seromucinous Carcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Surface Papillary Adenocarcinoma</condition>
  <condition>Recurrent Fallopian Tube Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <condition>Recurrent Primary Peritoneal Carcinoma</condition>
  <condition>Undifferentiated Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WEE1 Inhibitor AZD1775</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)</arm_group_label>
    <other_name>AZD-1775</other_name>
    <other_name>AZD1775</other_name>
    <other_name>MK-1775</other_name>
    <other_name>MK1775</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed epithelial ovarian,
             primary peritoneal and fallopian tube carcinoma; all histologic subtypes of
             epithelial ovarian cancer are eligible, but only patients with high grade serous
             ovarian cancer will be considered for the statistical analysis; non-high grade serous
             cancers will be allowed in an exploratory cohort

          -  Patients must be platinum-resistant (platinum-free interval &lt; 6 months) or have
             platinum-refractory disease as per Gynecologic Cancer Intergroup Committee (GCIC)
             criteria; disease progression has to be radiologic or clinical; biomarker progression
             with CA125 after a platinum based regimen would not be sufficient evidence of disease
             progression; the patients must have had radiological progression to that regimen

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as &gt; 10 mm with computed
             tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam

          -  There is no limitation in the number of prior lines of therapy

          -  Patients must have completed any prior chemotherapy, radiotherapy or major surgery at
             least 4 weeks before receiving study treatment; ongoing toxicities related to
             treatment must be =&lt; grade 1 and patients with grade 2 alopecia or peripheral
             neuropathy can also be included; palliative radiation to &lt; 10% of bone marrow is
             permissible if completed within one week of commencing study treatment as long as the
             toxicities secondary to palliative radiotherapy are limited to grade 1; the lesions
             that have received radiation treatment immediately before will be excluded as target
             lesions; previously irradiated lesions can be considered as targeted lesions, as long
             as there is prove of radiological progression

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Life expectancy of greater than 3 months

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 90 g/L

               -  Blood transfusions are allowed at any time during the screening, treatment or
                  follow-up period, according to the center recommendations

          -  Prothrombin time (PT), partial thromboplastin time (PTT) and international normalized
             ratio (INR) =&lt; 1.5 upper limit of normal (ULN)

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal; unless due to Gilbert's
             syndrome

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             institutional upper limit of normal (5 x if liver metastases)

          -  Creatinine =&lt; 1.5 Ã— institutional upper limit of normal OR creatinine clearance &gt;= 40
             mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional limit
             of normal

          -  Patients must be able to tolerate oral medication and not have evidence of active
             bowel obstruction

               -  Note: patients can have a history of prior bowel obstruction, provided the
                  patient is not having symptoms of bowel obstruction at the time of enrolment and
                  the bowel obstruction is not anticipated to recur during the participation in
                  the study

          -  Patients must have disease amenable to biopsy and must be willing to undergo a paired
             biopsy for correlative analyses (the first biopsy within 28 days prior to start of
             treatment and the second biopsy while on treatment)

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while she is participating in this study, she should inform her treating
             physician immediately

               -  Women of childbearing potential include women who have experienced menarche and
                  who have not undergone successful surgical sterilization (hysterectomy,
                  bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal;
                  postmenopause is defined as amenorrhea &gt;= 12 consecutive months; Note: women who
                  have been amenorrheic for 12 or more months are still considered to be of
                  childbearing potential if the amenorrhea is possibly due to prior chemotherapy,
                  anti-estrogens, ovarian suppression or any other reversible reason

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who previously received gemcitabine for the treatment of recurrent disease

          -  Patients who are receiving any other investigational agents

          -  Patients with clinically or radiologically unstable brain metastases are excluded
             from this clinical trial

               -  Note: patients with stable brain metastases after treatment, for at least 3
                  months prior to enrolling on this trial, could participate in the study;
                  patients should be off, or on a stable dose of steroids

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD 1775 (MK-1775) or gemcitabine

          -  Patients taking the following prescription or non-prescription drugs or other
             products (i.e. grapefruit juice) are ineligible: sensitive cytochrome P450 family 3,
             subfamily A, polypeptide 4 (CYP3A4) substrates, CYP3A4 substrates with a narrow
             therapeutic index, moderate to potent inhibitors/inducers of CYP3A4; patients would
             be eligible if the medications can be discontinued two weeks prior to day 1 of dosing
             and withheld throughout the study until 2 weeks after the last dose of study
             medication

          -  Pregnant and breastfeeding women are excluded from this study

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Uncontrolled intercurrent illness including, but not limited to, myocardial
             infarction within 6 months, congestive heart failure, symptomatic congestive heart
             failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular
             arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious
             infections, active peptic ulcer disease, active liver disease or cerebrovascular
             disease with previous stroke, or psychiatric illness/social situations that would
             limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Oza</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Morgan</last_name>
      <phone>626-256-4673</phone>
      <email>rmorgan@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert J. Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen C. Koehler</last_name>
      <phone>626-396-2900</phone>
      <email>skoehler@coh.org</email>
    </contact>
    <investigator>
      <last_name>Stephen C. Koehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gini F. Fleming</last_name>
      <phone>773-702-6712</phone>
      <email>gfleming@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Gini F. Fleming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Wade</last_name>
      <phone>217-876-6600</phone>
      <email>JLWADE3@sbcgloabal.net</email>
    </contact>
    <investigator>
      <last_name>James L. Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela E. Matei</last_name>
      <phone>317-278-8844</phone>
      <email>dmatei@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela E. Matei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>507-285-2411</phone>
      <email>wahnerhendrickson.andrea@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>612-863-8585</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina M. Mantia Smaldone</last_name>
      <phone>215-728-3175</phone>
      <email>gina.mantia-smaldone@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Gina M. Mantia Smaldone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander B. Olawaiye</last_name>
      <phone>412-641-1153</phone>
      <email>olawaiyea@mail.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander B. Olawaiye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>BCCA-Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan L. Ellard</last_name>
      <phone>250-712-3996</phone>
      <email>SEllard@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Susan L. Ellard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J. Hoskins</last_name>
      <phone>604-877-6000</phone>
      <email>phoskins@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Paul J. Hoskins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A. Welch</last_name>
      <phone>519-685-8640</phone>
      <email>stephen.welch@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen A. Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital and Cancer Center-General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanne I. Weberpals</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>76462</phone_ext>
      <email>jweberpals@Ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Johanne I. Weberpals</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network Princess Margaret Cancer Center P2C</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit M. Oza</last_name>
      <phone>416-946-2818</phone>
      <email>amit.oza@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Amit M. Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit M. Oza</last_name>
      <email>clinical.trials@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Amit M. Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane M. Provencher</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>27244</phone_ext>
      <email>diane.provencher.chum@ssss.gouv.gc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane M. Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Tan</last_name>
      <phone>65-6772-4140</phone>
      <email>david_sp_tan@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>David S. Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Adenocarcinoma, Papillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
